Business
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SAN JOSE, Calif., Aug. 26, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Aug. 26, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11, 2024 at the Lotte New York Palace Hotel in New York City.\n\n \n \n \n \n \n \n\n \nAnixa's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024, at 7:00 AM Eastern Time. A webcast of the Company's presentation can also be accessed at https://journey.ct.events/view/22198185-e09f-404c-a725-bf53bce656a8 and on the investor relations section of Company's website at https://ir.anixa.com/events.\nManagement will be participating in one-on-one meetings with investors throughout the conference in New York City. To request a meeting, please contact [email protected].\nAbout Anixa Biosciences, Inc.\nAnixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against \"retired\" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.\nForward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Privat...